Medrx Co

Medrx Co FCF Growth

The Year-over-Year Free Cash Flow Growth of Medrx Co (4586.T) as of Nov 19, 2026 is -20.86 %. In the previous year, Year-over-Year Free Cash Flow Growth was 12.09 % — a change of -272.54% (lower).

FCF Growth

-20.86 %

YoY

-272.54%

Last updated:

Year-over-Year Free Cash Flow Growth of Medrx Co is 2025 -20.86 % . Year-over-Year Free Cash Flow Growth of Medrx Co was 2024 12.09 % . It decreases by -272.54% lower compared to the previous year.

The Medrx Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-44.04 JPY
Jan 1, 2019
-38.07 JPY
Jan 1, 2020
43.05 JPY
Jan 1, 2021
9.61 JPY
Jan 1, 2022
-16.09 JPY
Jan 1, 2023
15.02 JPY
Jan 1, 2024
12.09 JPY
Jan 1, 2025
-20.86 JPY
The Medrx Co FCF Growth history
YEARFCF GrowthYoY
-20.86 %-272.54%
12.09 %-19.49%
15.02 %-193.35%
-16.09 %-267.34%
9.61 %-77.67%
43.05 %-213.08%
-38.07 %-13.55%
-44.04 %-269.72%
25.95 %-154.51%
-47.61 %-331.52%
20.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Year-over-Year Free Cash Flow Growth of Medrx Co is -20.86 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Medrx Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Medrx Co

All Key Metrics — Medrx Co